This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates
by Kinjel Shah
J&J (JNJ) updates its financial guidance for 2023 after the final separation of Kenvue. Pfizer, BioNTech, Merck and AbbVie announce regulatory developments.
Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for LVHD
Alkermes (ALKS) Grants Teva License to Market Generic Drug
by Zacks Equity Research
Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.
J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation
by Zacks Equity Research
With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
by Zacks Equity Research
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer
by Zacks Equity Research
Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%
by Zacks Equity Research
FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.
Medicare's First Price Negotiation List Targets Expensive Drugs
by Kinjel Shah
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
by Zacks Equity Research
Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid.
J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer
by Zacks Equity Research
J&J (JNJ) submits a supplemental new drug application to the FDA for full approval of Balversa to treat urothelial carcinoma.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
10 Drugs Selected for Medicare Price Reduction
by Zacks Equity Research
10 Drugs Selected for Medicare Price Reduction
Medicare Drugs Targeted Under Inflation Reduction Act
by Mark Vickery
Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.
AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Markets Up Second-Straight Day; Lots of Data On Deck
by Mark Vickery
All major indices are up over the past week of trading, though are still underwater for the past month.
J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer
by Zacks Equity Research
J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.
Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
by Zacks Equity Research
The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.
Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study
by Zacks Equity Research
With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and Eisai have decided to close the study.
AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan
by Zacks Equity Research
AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.
Novo Nordisk (NVO) Posts Upbeat Data From Heart Failure Study
by Zacks Equity Research
Novo Nordisk (NVO) announces positive results from its label-expanding study of Wegovy to treat patients with heart failure and obesity.
Novo Nordisk's (NVO) Shares Jump 17% in a Month: Here's Why
by Zacks Equity Research
Novo Nordisk's (NVO) commercial and pipeline progress with its popular obesity drug, Wegovy, continues to drive the share price momentum.
Emergent BioSolutions (EBS) Down 12% in a Week: Here's Why
by Zacks Equity Research
Shares of Emergent (EBS) are on a downward trajectory since the ticker was dropped from the S&P SmallCap 600 index.
Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation
by Kinjel Shah
FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
by Zacks Equity Research
AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.